Reducing Failure at the Most Expensive Preclinical Stage of Pharmaceutical Development
Reducing failure at the most expensive preclinical stage of pharmaceutical development
Lead optimization means the identification of new molecular entities and refinement of their structure to improve potency and pharmacokinetics while reducing off-target effects.
Traditionally involving in vitro and in vivo ADMET studies and data modeling methods such as QSARs, this stage consumes the largest share of finances in preclinical development.
The combination of high-quality, accessible data and powerful in silico profiling solutions has proven to accurately predict the potential of lead compounds. What’s more, it is less expensive than traditional methods and can provide greater coverage of compounds.
In this article, the value of higher-quality data, better in silico tools and improved data management is discussed in terms of the considerable potential for lead optimization.
To access the complimentary article 'Reducing failure at the most expensive preclinical stage of pharmaceutical development', please fill in the form below.
By submitting this form you also agree to receive information relevant to your interests from Elsevier B.V. and its affiliates worldwide. You can opt-out at any time by following the instructions given in the email messages you receive.
Elsevier's R&D Solutions supporting 'Reducing failure at the most expensive preclinical stage of pharmaceutical development'
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more about PharmaPendium